TNNT2 and amyotrophic lateral sclerosis: The compound monthly growth rate for cTnT was 0.045 points (IQR 0.02–0.08) in the ALS control cohort and 0.01 points (IQR −0.01–0.03) in the tofersen patients (p = 0.0013).